Human Albumin Baxalta (Human Serum Albumin)

Human Albumin Baxalta is indicated for clinical situations that demand rapid restoration of circulatory volume or supplementation of serum albumin.

• Hypovolemia resulting from trauma, surgery, or dehydration.
• Cardiogenic or distributive shock where plasma expansion is needed.
• Severe burns with fluid loss and protein depletion.
• Hypoalbuminemia associated with liver disease, nephrotic syndrome, or malnutrition.
• Adjunct therapy during large-volume paracentesis to prevent circulatory dysfunction.

• Human Albumin Baxalta provides exogenous albumin, the most abundant plasma protein, which contributes to oncotic pressure. By increasing the colloid osmotic gradient across the vascular endothelium, it draws water from the interstitial space into the intravascular compartment, thereby expanding plasma volume. This effect helps maintain hemodynamic stability during acute fluid loss.

Adverse reactions to Human Albumin Baxalta are reported across a range of frequencies and severities. These events may be related to the protein itself, to excipients, or to the rapid administration of a colloid solution.

Common

• Mild fever, chills, or rigors occurring during or shortly after the infusion.
• Transient changes in blood pressure, including temporary hypotension or hypertension.
• Localized skin reactions such as erythema, pruritus, or a mild maculopapular rash at the infusion site.

Serious

• Anaphylaxis or severe allergic reaction characterized by urticaria, bronchospasm, and hypotension.
• Acute respiratory distress, including bronchospasm, wheezing, or airway obstruction requiring intervention.
• Thromboembolic complications such as deep‑vein thrombosis, pulmonary embolism, or arterial occlusion.

Before using Human Albumin Baxalta, clinicians should evaluate patient history and clinical status to minimize risk and ensure appropriate use. Key considerations include volume status, cardiac function, and potential hypersensitivity.

• Assess intravascular volume and avoid over‑loading in patients with heart failure or renal impairment.
• Verify absence of known allergy to human albumin or any product components.
• Use caution in patients with a history of anaphylaxis or severe allergic reactions.
• Monitor vital signs and fluid balance during and after infusion.
• Adjust infusion rate in individuals at risk for circulatory overload or pulmonary edema.
• Consider alternative volume expanders when coagulopathy or active bleeding is present.

Human Albumin Baxalta may interact with other therapies that affect fluid balance, coagulation, or immune response, and clinicians should review concomitant medications. Potential interactions can alter efficacy or increase adverse event risk.

Avoid

• Simultaneous administration with other colloid solutions (e.g., hydroxyethyl starch) that may cause volume overload.
• Use with high‑dose diuretics without careful monitoring of electrolyte status.

Use with caution

• Concurrent use of anticoagulants or antiplatelet agents, as albumin can affect coagulation parameters.
• Co‑administration with vasopressors; hemodynamic response may be unpredictable.
• Infusion alongside immunoglobulins or blood products, which may increase risk of hypersensitivity.